Fennec Pharmaceuticals Inc (NASDAQ:FENC - Get Free Report) COO Adrian Haigh sold 22,222 shares of the firm's stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $9.91, for a total value of $220,220.02. Following the transaction, the chief operating officer now directly owns 22,222 shares of the company's stock, valued at approximately $220,220.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Adrian Haigh also recently made the following trade(s):
- On Monday, April 15th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $10.30, for a total value of $228,886.60.
Fennec Pharmaceuticals Stock Down 1.3 %
NASDAQ:FENC opened at $9.57 on Friday. Fennec Pharmaceuticals Inc has a 1-year low of $6.30 and a 1-year high of $11.92. The firm has a market capitalization of $259.35 million, a price-to-earnings ratio of -15.69 and a beta of 0.38. The stock has a fifty day simple moving average of $10.10 and a 200 day simple moving average of $9.33.
Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.12). The company had revenue of $9.74 million during the quarter, compared to analysts' expectations of $9.47 million. Equities analysts predict that Fennec Pharmaceuticals Inc will post 0.11 earnings per share for the current year.
Institutional Investors Weigh In On Fennec Pharmaceuticals
Urgent Nvidia Warning
From Altimetry | Ad
Could Steve Job's 'Final Prophecy' Make You Rich?
Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.
Click here to access…
Several hedge funds have recently bought and sold shares of the business. Sonic GP LLC purchased a new stake in shares of Fennec Pharmaceuticals during the 4th quarter worth about $23,111,000. Vanguard Group Inc. raised its stake in shares of Fennec Pharmaceuticals by 1,294.3% during the 4th quarter. Vanguard Group Inc. now owns 1,140,063 shares of the company's stock worth $12,792,000 after purchasing an additional 1,058,295 shares in the last quarter. BlackRock Inc. raised its stake in shares of Fennec Pharmaceuticals by 1,507.6% during the 2nd quarter. BlackRock Inc. now owns 830,119 shares of the company's stock worth $7,330,000 after purchasing an additional 778,481 shares in the last quarter. AIGH Capital Management LLC raised its stake in shares of Fennec Pharmaceuticals by 6.9% during the 3rd quarter. AIGH Capital Management LLC now owns 373,526 shares of the company's stock worth $2,805,000 after purchasing an additional 24,069 shares in the last quarter. Finally, Gendell Jeffrey L raised its stake in shares of Fennec Pharmaceuticals by 0.9% during the 3rd quarter. Gendell Jeffrey L now owns 285,992 shares of the company's stock worth $2,148,000 after purchasing an additional 2,579 shares in the last quarter. 55.51% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on FENC. Wedbush reaffirmed an "outperform" rating and set a $16.00 target price on shares of Fennec Pharmaceuticals in a research note on Monday, March 18th. HC Wainwright increased their price target on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a "buy" rating in a research report on Thursday, April 4th. Finally, Craig Hallum increased their price target on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a "buy" rating in a research report on Monday, March 18th.
Check Out Our Latest Research Report on FENC
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
